zheng zhu - Infectious Diseases

Author Information

Zheng Zhu is a researcher affiliated with the State Key Laboratory of Emerging Infectious Diseases at The University of Hong Kong, located in Pokfulam, Hong Kong Special Administrative Region, China. Zhu's work focuses on the field of infectious diseases, with a particular emphasis on viral pathogens and host-pathogen interactions.

Research Contributions

Zheng Zhu has made significant contributions to the study of infectious diseases, particularly in the context of viral infections such as Zika virus, MERS-CoV, and novel coronaviruses. Zhu's research includes the exploration of host-targeting antiviral strategies and the genomic characterization of emerging viruses. Notably, Zhu has been involved in studies identifying host dependency factors necessary for virus propagation and investigating antiviral mechanisms targeting specific viral proteins and pathways. Zhu's work also extends to the profiling of microRNAs in the context of HIV-1 infection, indicating a broad interest in viral pathogenesis and immune responses.

Aliases

No aliases are provided for Zheng Zhu in the available information.

Publication and Citation Metrics

Metric	Value
Total Citation Count	3850
h-index	17
Total Paper Count	23

Publications:

Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation

DOI: 10.1080/22221751.2020.1738277

Year: 2020

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

DOI: 10.1080/22221751.2020.1719902

Year: 2020

Targeting the inositol-requiring enzyme-1 pathway efficiently reverts Zika virus-induced neurogenesis and spermatogenesis marker perturbations.

DOI: 10.1021/acsinfecdis.9b00526

Year: 2020

Targeting SUMO Modification of the Non-Structural Protein 5 of Zika Virus as a Host-Targeting Antiviral Strategy

DOI: 10.3390/ijms20020392

Year: 2019

Identification of a Novel Ichthyic Parvovirus in Marine Species in Hainan Island, China

DOI: 10.3389/fmicb.2019.02815

Year: 2019

The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy

DOI: 10.1016/j.antiviral.2018.10.007

Year: 2018

Structure‐based discovery of clinically approved drugs as Zika virus NS2B‐NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo

DOI: 10.1016/j.antiviral.2017.07.007

Year: 2017

MicroRNA profiling in plasma of HIV-1 infected patients: potential markers of infection and immune status

DOI: 10.21037/JPHE.2017.05.11

Year: 2017

Novel antiviral activity and mechanism of bromocriptine as a Zika virus NS2B‐NS3 protease inhibitor

DOI: 10.1016/j.antiviral.2017.02.002

Year: 2017

First detection and complete genome sequence of a phylogenetically distinct human polyomavirus 6 highly prevalent in human bile samples.

DOI: 10.1016/j.jinf.2016.11.002

Year: 2017

What is the global impact of Dengvaxia?

What is Plasmodium?

How Does Surveillance Help in Managing Infectious Diseases?

How Does the FDA Approve Vaccines?

Are There Risks Associated with Antipyretic Use?

What Are Some Key Infectious Diseases of Global Concern?

How Can Zika Virus Be Prevented?

Why are Zoonotic Diseases Important?

How Do Environmental Factors Influence These Interactions?

What are Zoonoses?

Partnered Content Networks

Relevant Topics